Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Cancer of Unknown Primary | Case report

Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review

Authors: Masanobu Abe, Kousuke Watanabe, Aya Shinozaki-Ushiku, Tetsuo Ushiku, Takahiro Abe, Yuko Fujihara, Yosuke Amano, Liang Zong, Cheng-Ping Wang, Emi Kubo, Ryoko Inaki, Naoya Kinoshita, Satoshi Yamashita, Daiya Takai, Toshikazu Ushijima, Takahide Nagase, Kazuto Hoshi

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Cancers of unknown primary origin (CUPs) are reported to be the 3-4th most common causes of cancer death. Recent years have seen advances in mutational analysis and genomics profiling. These advances could improve accuracy of diagnosis of CUPs and might improve the prognosis of patients with CUPs.

Case presentation

A 76-year old male with an adenocarcinoma of unknown primary origin in the lung presented with another tumor of the palate mucosa. The tumor cells in the pleural effusion were all negative for immunohistochemical markers (TTF-1 and Napsin A) and lung-specific oncogenic driver alterations (EGFR mutation and ALK translocation). The tumor of the palate mucosa was likewise identified as an adenocarcinoma, and the cells showed cytological similarities with the tumor cells in the pleural effusion; TTF-1, Napsin A, EGFR mutation and ALK translocation were all negative. This result suggested that origins of the tumors of the palate mucosa and in the lung were the same, even though the origin had not yet been determined. Next, we addressed whether the tumor of the palate mucosa was a primary tumor or not. Secretory carcinoma (SC), which is a common type of minor salivary gland tumor (MSGT), was suspected; however, mammaglobin was negative and ETV6-NTRK3 (EN) fusion was not observed. Other MSGTs were excluded based on histological and immunohistochemical findings. Furthermore, an additional examination demonstrated an oncogenic KRAS mutation at codon 12 (p.G12D) in both palate tumor and in pleural effusion. KRAS mutation is known to exist in one-third of lung adenocarcinomas (LUADs), but quite rare in MSGTs. The possibility of metastasis from other organs was considered unlikely from the results of endoscopic and imaging studies. This result indicated that the primary site of the CUP was indeed the lung, and that the tumor of the palate mucosa was a metastasis of the LUAD.

Conclusions

A tumor of the palate mucosa that showed diagnostic difficulties was determined to be a metastatic LUAD by genomic alterations and histopathological findings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Choi J, Nahm JH, Kim SK. Prognostic clinicopathologic factors in carcinoma of unknown primary origin: a study of 106 consecutive cases. Oncotarget. 2017;8(37):62630–40. Choi J, Nahm JH, Kim SK. Prognostic clinicopathologic factors in carcinoma of unknown primary origin: a study of 106 consecutive cases. Oncotarget. 2017;8(37):62630–40.
2.
go back to reference Jones W, Allardice G, Scott I, Oien K, Brewster D, Morrison DS. Cancers of unknown primary diagnosed during hospitalization: a population-based study. BMC Cancer. 2017;17(1):85.CrossRef Jones W, Allardice G, Scott I, Oien K, Brewster D, Morrison DS. Cancers of unknown primary diagnosed during hospitalization: a population-based study. BMC Cancer. 2017;17(1):85.CrossRef
3.
go back to reference Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, Palmer G, Yelensky R, Lipson DM, Chmielecki J, et al. Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol. 2015;1(1):40–9.CrossRef Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, Palmer G, Yelensky R, Lipson DM, Chmielecki J, et al. Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol. 2015;1(1):40–9.CrossRef
4.
go back to reference Moran S, Martinez-Cardus A, Boussios S, Esteller M. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary. Nat Rev Clin Oncol. 2017;14(11):682–94. Moran S, Martinez-Cardus A, Boussios S, Esteller M. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary. Nat Rev Clin Oncol. 2017;14(11):682–94.
5.
go back to reference Aydil U, Kizil Y, Bakkal FK, Koybasioglu A, Uslu S. Neoplasms of the hard palate. J Oral Maxillofac Surg. 2014;72(3):619–26.CrossRef Aydil U, Kizil Y, Bakkal FK, Koybasioglu A, Uslu S. Neoplasms of the hard palate. J Oral Maxillofac Surg. 2014;72(3):619–26.CrossRef
6.
go back to reference Abe M, Inaki R, Kanno Y, Hoshi K, Takato T. Molecular analysis of a mammary analog secretory carcinoma in the upper lip: novel search for genetic and epigenetic abnormalities in MASC. Int J Surg Case Rep. 2015;9:8–11.CrossRef Abe M, Inaki R, Kanno Y, Hoshi K, Takato T. Molecular analysis of a mammary analog secretory carcinoma in the upper lip: novel search for genetic and epigenetic abnormalities in MASC. Int J Surg Case Rep. 2015;9:8–11.CrossRef
7.
go back to reference Inaki R, Abe M, Zong L, Abe T, Shinozaki-Ushiku A, Ushiku T, Hoshi K. Secretory carcinoma - impact of translocation and gene fusions on salivary gland tumor. Chin J Cancer Res. 2017;29(5):379–84.CrossRef Inaki R, Abe M, Zong L, Abe T, Shinozaki-Ushiku A, Ushiku T, Hoshi K. Secretory carcinoma - impact of translocation and gene fusions on salivary gland tumor. Chin J Cancer Res. 2017;29(5):379–84.CrossRef
8.
go back to reference Abe M, Yamashita S, Mori Y, Abe T, Saijo H, Hoshi K, Ushijima T, Takato T. High-risk oral leukoplakia is associated with aberrant promoter methylation of multiple genes. BMC Cancer. 2016;16(1):350.CrossRef Abe M, Yamashita S, Mori Y, Abe T, Saijo H, Hoshi K, Ushijima T, Takato T. High-risk oral leukoplakia is associated with aberrant promoter methylation of multiple genes. BMC Cancer. 2016;16(1):350.CrossRef
9.
go back to reference Khalele BA. Systematic review of mammary analog secretory carcinoma of salivary glands at 7 years after description. Head Neck. 2017;39(6):1243–8.CrossRef Khalele BA. Systematic review of mammary analog secretory carcinoma of salivary glands at 7 years after description. Head Neck. 2017;39(6):1243–8.CrossRef
10.
go back to reference Rajinikanth M, Prakash AR, Swathi TR, Reddy S. Metastasis of lung adenocarcinoma to the jaw bone. J Oral Maxillofac Pathol. 2015;19(3):385–8.CrossRef Rajinikanth M, Prakash AR, Swathi TR, Reddy S. Metastasis of lung adenocarcinoma to the jaw bone. J Oral Maxillofac Pathol. 2015;19(3):385–8.CrossRef
11.
go back to reference Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R. Metastatic tumours to the oral cavity - pathogenesis and analysis of 673 cases. Oral Oncol. 2008;44(8):743–52.CrossRef Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R. Metastatic tumours to the oral cavity - pathogenesis and analysis of 673 cases. Oral Oncol. 2008;44(8):743–52.CrossRef
12.
go back to reference Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol. 2015;16(7):e342–51.CrossRef Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol. 2015;16(7):e342–51.CrossRef
13.
go back to reference Yin LX, Ha PK. Genetic alterations in salivary gland cancers. Cancer. 2016;122(12):1822–31.CrossRef Yin LX, Ha PK. Genetic alterations in salivary gland cancers. Cancer. 2016;122(12):1822–31.CrossRef
14.
go back to reference Nishikawa G, Sekine S, Ogawa R, Matsubara A, Mori T, Taniguchi H, Kushima R, Hiraoka N, Tsuta K, Tsuda H, et al. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br J Cancer. 2013;108(4):951–8.CrossRef Nishikawa G, Sekine S, Ogawa R, Matsubara A, Mori T, Taniguchi H, Kushima R, Hiraoka N, Tsuta K, Tsuda H, et al. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br J Cancer. 2013;108(4):951–8.CrossRef
15.
go back to reference Lohinai Z, Klikovits T, Moldvay J, Ostoros G, Raso E, Timar J, Fabian K, Kovalszky I, Kenessey I, Aigner C, et al. KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Sci Rep. 2017;7:39721.CrossRef Lohinai Z, Klikovits T, Moldvay J, Ostoros G, Raso E, Timar J, Fabian K, Kovalszky I, Kenessey I, Aigner C, et al. KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Sci Rep. 2017;7:39721.CrossRef
16.
go back to reference Dahse R, Driemel O, Schwarz S, Kromeyer-Hauschild K, Berndt A, Kosmehl H. KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas. Oral Oncol. 2009;45(9):826–9.CrossRef Dahse R, Driemel O, Schwarz S, Kromeyer-Hauschild K, Berndt A, Kosmehl H. KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas. Oral Oncol. 2009;45(9):826–9.CrossRef
17.
go back to reference Wang QJ, Yu Z, Griffith K, Hanada K, Restifo NP, Yang JC. Identification of T-cell receptors targeting KRAS-mutated human tumors. Cancer Immunol Res. 2016;4(3):204–14.CrossRef Wang QJ, Yu Z, Griffith K, Hanada K, Restifo NP, Yang JC. Identification of T-cell receptors targeting KRAS-mutated human tumors. Cancer Immunol Res. 2016;4(3):204–14.CrossRef
18.
go back to reference Varadhachary GR, Raber MN. Carcinoma of unknown primary site. N Engl J Med. 2014;371(21):2040.CrossRef Varadhachary GR, Raber MN. Carcinoma of unknown primary site. N Engl J Med. 2014;371(21):2040.CrossRef
19.
go back to reference Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379(9824):1428–35.CrossRef Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379(9824):1428–35.CrossRef
20.
go back to reference Raghav K, Mhadgut H, McQuade JL, Lei X, Ross A, Matamoros A, Wang H, Overman MJ, Varadhachary GR. Cancer of unknown primary in adolescents and young adults: Clinicopathological features, prognostic factors and survival outcomes. PLoS One. 2016;11(5):e0154985.CrossRef Raghav K, Mhadgut H, McQuade JL, Lei X, Ross A, Matamoros A, Wang H, Overman MJ, Varadhachary GR. Cancer of unknown primary in adolescents and young adults: Clinicopathological features, prognostic factors and survival outcomes. PLoS One. 2016;11(5):e0154985.CrossRef
21.
go back to reference Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013;31(2):217–23.CrossRef Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013;31(2):217–23.CrossRef
22.
go back to reference Uzunoglu S, Erdogan B, Kodaz H, Cinkaya A, Turkmen E, Hacibekiroglu I, Sari A, Ozen A, Usta U, Cicin I. Unknown primary adenocarcinomas: a single-center experience. Bosn J Basic Med Sci. 2016;16(4):292–7.PubMedPubMedCentral Uzunoglu S, Erdogan B, Kodaz H, Cinkaya A, Turkmen E, Hacibekiroglu I, Sari A, Ozen A, Usta U, Cicin I. Unknown primary adenocarcinomas: a single-center experience. Bosn J Basic Med Sci. 2016;16(4):292–7.PubMedPubMedCentral
23.
go back to reference Sagheb K, Manz A, Albrich SB, Taylor KJ, Hess G, Walter C. Supraclavicular metastases from distant primary solid Tumours: a retrospective study of 41 years. J Maxillofac Oral Surg. 2017;16(2):152–7.CrossRef Sagheb K, Manz A, Albrich SB, Taylor KJ, Hess G, Walter C. Supraclavicular metastases from distant primary solid Tumours: a retrospective study of 41 years. J Maxillofac Oral Surg. 2017;16(2):152–7.CrossRef
24.
go back to reference Overgaard J, Jovanovic A, Godballe C, Grau Eriksen J. The Danish head and neck Cancer database. Clin Epidemiol. 2016;8:491–6.CrossRef Overgaard J, Jovanovic A, Godballe C, Grau Eriksen J. The Danish head and neck Cancer database. Clin Epidemiol. 2016;8:491–6.CrossRef
25.
go back to reference Lanzer M, Bachna-Rotter S, Graupp M, Bredell M, Rucker M, Huber G, Reinisch S, Schumann P. Unknown primary of the head and neck: a long-term follow-up. J Craniomaxillofac Surg. 2015;43(4):574–9.CrossRef Lanzer M, Bachna-Rotter S, Graupp M, Bredell M, Rucker M, Huber G, Reinisch S, Schumann P. Unknown primary of the head and neck: a long-term follow-up. J Craniomaxillofac Surg. 2015;43(4):574–9.CrossRef
26.
go back to reference Balaker AE, Abemayor E, Elashoff D, St John MA. Cancer of unknown primary: does treatment modality make a difference? Laryngoscope. 2012;122(6):1279–82.CrossRef Balaker AE, Abemayor E, Elashoff D, St John MA. Cancer of unknown primary: does treatment modality make a difference? Laryngoscope. 2012;122(6):1279–82.CrossRef
27.
go back to reference Sivars L, Bersani C, Grun N, Ramqvist T, Munck-Wikland E, Von Buchwald C, Dalianis T. Human papillomavirus is a favourable prognostic factor in cancer of unknown primary in the head and neck region and in hypopharyngeal cancer. Mol Clin Oncol. 2016;5(6):671–4.CrossRef Sivars L, Bersani C, Grun N, Ramqvist T, Munck-Wikland E, Von Buchwald C, Dalianis T. Human papillomavirus is a favourable prognostic factor in cancer of unknown primary in the head and neck region and in hypopharyngeal cancer. Mol Clin Oncol. 2016;5(6):671–4.CrossRef
28.
go back to reference Sivars L, Nasman A, Tertipis N, Vlastos A, Ramqvist T, Dalianis T, Munck-Wikland E, Nordemar S. Human papillomavirus and p53 expression in cancer of unknown primary in the head and neck region in relation to clinical outcome. Cancer Med. 2014;3(2):376–84.CrossRef Sivars L, Nasman A, Tertipis N, Vlastos A, Ramqvist T, Dalianis T, Munck-Wikland E, Nordemar S. Human papillomavirus and p53 expression in cancer of unknown primary in the head and neck region in relation to clinical outcome. Cancer Med. 2014;3(2):376–84.CrossRef
29.
go back to reference Sivars L, Tani E, Nasman A, Ramqvist T, Munck-Wikland E, Dalianis T. Human papillomavirus as a diagnostic and prognostic tool in Cancer of unknown primary in the head and neck region. Anticancer Res. 2016;36(2):487–93.PubMed Sivars L, Tani E, Nasman A, Ramqvist T, Munck-Wikland E, Dalianis T. Human papillomavirus as a diagnostic and prognostic tool in Cancer of unknown primary in the head and neck region. Anticancer Res. 2016;36(2):487–93.PubMed
30.
go back to reference Abe M, Okochi E, Kuramoto T, Kaneda A, Takato T, Sugimura T, Ushijima T. Cloning of the 5′ upstream region of the rat p16 gene and its role in silencing. Jpn J Cancer Res. 2002;93(10):1100–6.CrossRef Abe M, Okochi E, Kuramoto T, Kaneda A, Takato T, Sugimura T, Ushijima T. Cloning of the 5′ upstream region of the rat p16 gene and its role in silencing. Jpn J Cancer Res. 2002;93(10):1100–6.CrossRef
31.
go back to reference Dixon PR, Au M, Hosni A, Perez-Ordonez B, Weinreb I, Xu W, Song Y, Huang SH, O'Sullivan B, Goldstein DP, et al. Impact of p16 expression, nodal status, and smoking on oncologic outcomes of patients with head and neck unknown primary squamous cell carcinoma. Head Neck. 2016;38(9):1347–53.CrossRef Dixon PR, Au M, Hosni A, Perez-Ordonez B, Weinreb I, Xu W, Song Y, Huang SH, O'Sullivan B, Goldstein DP, et al. Impact of p16 expression, nodal status, and smoking on oncologic outcomes of patients with head and neck unknown primary squamous cell carcinoma. Head Neck. 2016;38(9):1347–53.CrossRef
32.
go back to reference Schroeder L, Boscolo-Rizzo P, Dal Cin E, Romeo S, Baboci L, Dyckhoff G, Hess J, Lucena-Porcel C, Byl A, Becker N, et al. Human papillomavirus as prognostic marker with rising prevalence in neck squamous cell carcinoma of unknown primary: a retrospective multicentre study. Eur J Cancer. 2017;74:73–81.CrossRef Schroeder L, Boscolo-Rizzo P, Dal Cin E, Romeo S, Baboci L, Dyckhoff G, Hess J, Lucena-Porcel C, Byl A, Becker N, et al. Human papillomavirus as prognostic marker with rising prevalence in neck squamous cell carcinoma of unknown primary: a retrospective multicentre study. Eur J Cancer. 2017;74:73–81.CrossRef
33.
go back to reference Wood K, Hensing T, Malik R, Salgia R. Prognostic and predictive value in KRAS in non-small-cell lung Cancer: a review. JAMA Oncol. 2016;2(6):805–12.CrossRef Wood K, Hensing T, Malik R, Salgia R. Prognostic and predictive value in KRAS in non-small-cell lung Cancer: a review. JAMA Oncol. 2016;2(6):805–12.CrossRef
34.
go back to reference Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457–67.CrossRef Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457–67.CrossRef
35.
go back to reference Cserepes M, Ostoros G, Lohinai Z, Raso E, Barbai T, Timar J, Rozsas A, Moldvay J, Kovalszky I, Fabian K, et al. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. Eur J Cancer. 2014;50(10):1819–28.CrossRef Cserepes M, Ostoros G, Lohinai Z, Raso E, Barbai T, Timar J, Rozsas A, Moldvay J, Kovalszky I, Fabian K, et al. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. Eur J Cancer. 2014;50(10):1819–28.CrossRef
36.
go back to reference Tan WL, Jain A, Takano A, Newell EW, Iyer NG, Lim WT, Tan EH, Zhai W, Hillmer AM, Tam WL, et al. Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol. 2016;17(8):e347–62.CrossRef Tan WL, Jain A, Takano A, Newell EW, Iyer NG, Lim WT, Tan EH, Zhai W, Hillmer AM, Tam WL, et al. Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol. 2016;17(8):e347–62.CrossRef
37.
go back to reference Illei PB, Belchis D, Tseng LH, Nguyen D, De Marchi F, Haley L, Riel S, Beierl K, Zheng G, Brahmer JR, et al. Clinical mutational profiling of 1006 lung cancers by next generation sequencing. Oncotarget. 2017. Illei PB, Belchis D, Tseng LH, Nguyen D, De Marchi F, Haley L, Riel S, Beierl K, Zheng G, Brahmer JR, et al. Clinical mutational profiling of 1006 lung cancers by next generation sequencing. Oncotarget. 2017.
38.
go back to reference Warth A, Penzel R, Lindenmaier H, Brandt R, Stenzinger A, Herpel E, Goeppert B, Thomas M, Herth FJ, Dienemann H, et al. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J. 2014;43(3):872–83.CrossRef Warth A, Penzel R, Lindenmaier H, Brandt R, Stenzinger A, Herpel E, Goeppert B, Thomas M, Herth FJ, Dienemann H, et al. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J. 2014;43(3):872–83.CrossRef
39.
go back to reference Fu Y, Cruz-Monserrate Z, Helen Lin H, Chung Y, Ji B, Lin SM, Vonderfecht S, Logsdon CD, Li CF, Ann DK. Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype. Sci Rep. 2015;5:13347.CrossRef Fu Y, Cruz-Monserrate Z, Helen Lin H, Chung Y, Ji B, Lin SM, Vonderfecht S, Logsdon CD, Li CF, Ann DK. Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype. Sci Rep. 2015;5:13347.CrossRef
40.
go back to reference Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, Schilsky RL. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015. J Clin Oncol. 2016;34(2):179–85.CrossRef Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, Schilsky RL. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015. J Clin Oncol. 2016;34(2):179–85.CrossRef
41.
go back to reference Hainsworth JD, Anthony Greco F. Lung adenocarcinoma with anaplastic lymphoma kinase (ALK) rearrangement presenting as carcinoma of unknown primary site: recognition and treatment implications. Drugs Real World Outcomes. 2016;3(1):115–20.CrossRef Hainsworth JD, Anthony Greco F. Lung adenocarcinoma with anaplastic lymphoma kinase (ALK) rearrangement presenting as carcinoma of unknown primary site: recognition and treatment implications. Drugs Real World Outcomes. 2016;3(1):115–20.CrossRef
42.
go back to reference Kim JH, Kim HS, Kim BJ. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: a metaanalysis and review. Oncotarget. 2017;8(29):48248–52. Kim JH, Kim HS, Kim BJ. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: a metaanalysis and review. Oncotarget. 2017;8(29):48248–52.
Metadata
Title
Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review
Authors
Masanobu Abe
Kousuke Watanabe
Aya Shinozaki-Ushiku
Tetsuo Ushiku
Takahiro Abe
Yuko Fujihara
Yosuke Amano
Liang Zong
Cheng-Ping Wang
Emi Kubo
Ryoko Inaki
Naoya Kinoshita
Satoshi Yamashita
Daiya Takai
Toshikazu Ushijima
Takahide Nagase
Kazuto Hoshi
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5277-1

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine